Moreau P, Stewart KA, Dimopoulos M, et al. - Given that the combination of carfilzomib with dexamethasone (Kd) is approved for use in relapsed and/or refractory multiple myeloma (RRMM), with carfilzomib administered twice weekly at 56 mg/m² (Kd56 BIW) or once weekly at 70 mg/m² (Kd70 QW), researchers sought to compare effectiveness and safety profiles of Kd70 QW vs Kd56 BIW dosing schedules utilizing data from three trials of patients with RRMM: A.R.R.O.W., CHAMPION-1, and ENDEAVOR. Data reported that the overall response rate (ORR) was 69.9% for Kd70 QW and 72.4% for Kd56 BIW. Regression analyses of all individuals in the trials who took Kd70 QW compared with Kd56 BIW estimated a PFS hazard ratio of 0.91 and an ORR odds ratio of 1.12. Such outcomes indicate that Kd70 QW has a similar efficacy profile vs Kd56 BIW, and is a convenient and well-tolerated treatment for RRMM patients.